BioMarin Pharmaceutical Inc. $BMRN Holdings Cut by Rafferty Asset Management LLC

Rafferty Asset Management LLC lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 12.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 151,015 shares of the biotechnology company’s stock after selling 20,508 shares during the period. Rafferty Asset Management LLC owned about 0.08% of BioMarin Pharmaceutical worth $8,179,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BMRN. Dodge & Cox boosted its position in BioMarin Pharmaceutical by 1.0% during the second quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company’s stock valued at $830,504,000 after purchasing an additional 153,070 shares during the last quarter. Viking Global Investors LP raised its stake in shares of BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of BioMarin Pharmaceutical by 90.7% during the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after purchasing an additional 2,654,768 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of BioMarin Pharmaceutical by 1.3% during the 2nd quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock valued at $190,417,000 after buying an additional 43,185 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $112,352,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $61.73 on Monday. The firm has a market capitalization of $11.87 billion, a PE ratio of 34.68, a PEG ratio of 0.54 and a beta of 0.25. BioMarin Pharmaceutical Inc. has a 1 year low of $50.76 and a 1 year high of $73.51. The company has a current ratio of 5.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.10. The firm’s fifty day simple moving average is $58.91 and its 200 day simple moving average is $56.17.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BMRN shares. Piper Sandler cut their price objective on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Guggenheim cut their price target on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Stifel Nicolaus set a $68.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, February 24th. Oppenheimer lowered their target price on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 24th. Finally, Sanford C. Bernstein raised their target price on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Fifteen analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.71.

Insider Activity at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares in the company, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.